New method for early detection of epithelial ovarian cancer using blood samples

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on developing a highly sensitive and specific SERS chip for the early diagnosis of epithelial ovarian cancer. By analyzing blood samples from ovarian cancer patients and healthy controls, the study aims to identify distinct cancer signals and construct a statistical model for diagnosis. The research utilizes advanced femtosecond laser processing technology to enhance the detection of key biomolecules, ultimately providing a foundation for improved screening methods. The study will also explore the interaction patterns between SERS active particles and biomolecules to refine the diagnostic process.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. The subjects understand the trial process, sign the informed consent form, voluntarily participate in the study, and are capable of following the protocol;
2. Aged 18 to 70 (inclusive):

Cancer group: Ovarian cancer patients (50 cases of high-grade serous ovarian cancer, 15 cases of low-grade serous ovarian cancer, 20 cases of endometrioid ovarian cancer, 20 cases of clear cell carcinoma) i. All ovarian cancer patients are initial treatment patients with complete clinical data; ii. Patients have an ECOG performance status score of 0-3 and a life expectancy of more than 6 months; iii. Subjects consent to blood sample collection for SERS analysis (provided free of charge); iv. Good organ function.

Normal control group: (20 cases) i. Normal control subjects are patients undergoing surgery for benign diseases; ii. Patients have complete clinical data; iii. Subjects have not undergone any radical treatment for the benign lesion prior to blood collection.

Exclusion Criteria:

1. Severe or uncontrolled diseases, including but not limited to: uncontrollable nausea and vomiting, gastrointestinal diseases that may interfere with drug absorption and metabolism, mental illnesses affecting the patient's ability to sign the informed consent form, a history of severe cardiovascular disease, infectious diseases (such as syphilis, AIDS, active hepatitis C, or active hepatitis B), infectious conditions (such as abscesses), or active rheumatic diseases, etc.;
2. A history of blood transfusion within 4 weeks prior to the study;
3. Pregnant, postpartum, or breastfeeding patients, or patients planning to become pregnant during the study treatment;
4. Patients with a history of other tumors;
5. The investigator deems the subject unsuitable for participation in this clinical study.

Where it's running

• Anhui Provincal Hospital
  Hefei, Anhui, China Recruiting

Study contacts

• Study coordinator: Ying Zhou, MD
• Email: caddiezy@ustc.edu.cn
• Phone: _8613865901025

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating NX-1607 for advanced cancers

  This study is testing a new treatment called NX-1607 to see if it can help people with advanced cancers who have run out of other options.

  Recruiting at 15 sites Phase 1 Nurix Therapeutics, Inc. · Duarte, California and 16 other locations · NCT05107674

• Comparing two treatment methods for advanced ovarian cancer

  This study is testing which chemotherapy method works better for people with advanced ovarian cancer after surgery.

  Recruiting at 7 sites Phase 2 Groupe Hospitalier Diaconesses Croix Saint-Simon · Dijon and 6 other locations · NCT03025477

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• Multimodal Survival Predictor for Colorectal Liver Metastases After Surgery

  Researchers are testing a tool that combines MRI-derived tumor features with clinical data to predict survival after surgery for colorectal liver metastases.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07830576

• Zinc add-on with targeted therapy plus immunotherapy for advanced liver cancer

  This study tests whether adding daily zinc to standard targeted therapy and immunotherapy helps people with unresectable or advanced hepatocellular carcinoma.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07793695

• Reconstruction kinetics of γδ T cells after an unrelated cord blood transplant

  This study tests how γδ T cells recover after an unrelated cord blood transplant and whether recovery patterns relate to outcomes like graft-versus-host disease, relapse, and survival.

  Recruiting Anhui Provincial Hospital · Hefei, Anhui · NCT07782684

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.